Rhumbline Advisers Purchases 9,514 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Rhumbline Advisers boosted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 4.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 223,115 shares of the biopharmaceutical company’s stock after purchasing an additional 9,514 shares during the period. Rhumbline Advisers owned 0.14% of Ocular Therapeutix worth $1,635,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in shares of Ocular Therapeutix during the fourth quarter worth about $28,000. Atlas Capital Advisors Inc. acquired a new stake in Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at $53,000. GAMMA Investing LLC raised its stake in shares of Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 8,112 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 8,446 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

OCUL has been the subject of a number of recent research reports. Royal Bank Of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC decreased their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Finally, William Blair started coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Ocular Therapeutix Trading Down 5.1%

Shares of OCUL stock opened at $8.30 on Wednesday. The company has a market cap of $1.32 billion, a P/E ratio of -7.22 and a beta of 1.42. Ocular Therapeutix, Inc. has a fifty-two week low of $5.34 and a fifty-two week high of $11.78. The stock has a 50 day simple moving average of $7.79 and a two-hundred day simple moving average of $7.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22.

Insider Activity

In other news, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction on Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now owns 172,704 shares of the company’s stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pravin Dugel sold 21,219 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,079 shares of company stock worth $208,739 in the last quarter. 2.30% of the stock is owned by corporate insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.